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Organic acidurias (OAD) and urea-cycle disorders (UCD) are rare inherited disorders
affecting amino acid and protein metabolism. As dietary practice varies widely, we
assessed their long-term prescribed dietary treatment against published guideline and
studied plasma amino acids levels. We analyzed data from the first visit recorded in
the European registry and network for intoxication type metabolic diseases (E-IMD,
Chafea no. 2010 12 01). In total, 271 methylmalonic aciduria (MMA) and propionic
aciduria (PA) and 361 UCD patients were included. Median natural protein prescrip-
tion was consistent with the recommended daily allowance (RDA), plasma L-valine
(57%), and L-isoleucine (55%) levels in MMA and PA lay below reference ranges.
Plasma levels were particularly low in patients who received amino acid mixtures
(AAMs-OAD) and L-isoleucine:L-leucine:L-valine (BCAA) ratio was 1.0:3.0:3.2. In
UCD patients, plasma L-valine, L-isoleucine, and L-leucine levels lay below refer-
ence ranges in 18%, 30%, and 31%, respectively. In symptomatic UCD patients who
received AAM-UCD, the median natural protein prescription lay below RDA, while
their L-valine and L-isoleucine levels and plasma BCAA ratios were comparable to
those in patients who did not receive AAM-UCD. Notably, in patients with ornithine
transcarbamylase syndrome (OTC-D), carbamylphosphate synthetase 1 syndrome
(CPS1-D) and hyperammonemia-hyperornithinemia-homocitrullinemia (HHH) syn-
drome selective L-citrulline supplementation resulted in higher plasma L-arginine
levels than selective L-arginine supplementation. In conclusion, while MMA and PA
patients who received AAMs-OAD had very low BCAA levels and disturbed plasma
Abbreviations: AAM(s), amino acid mixture(s); AAM(s)-OAD, amino acid
mixture(s) for organic acidemias (lack L-isoleucine and L-valine); AAM(s)-
UCD, amino acid mixture(s) for urea-cycle disorders (contain essential
amino acids); ASL(-D), argininosuccinate lyase (deficiency); ASS(-D), argi-
ninosuccinate synthetase (deficiency); BCAAs, branched-chain amino acids;
CPS1(-D), carbamylphosphate synthetase 1 (deficiency); E-IMD, European
registry and network for intoxication type metabolic diseases; HHH, hyper-
ornithinemia-hyperammonemia-homocitrullinuria; MMA, methylmalonic
aciduria; OAD, organic acidurias; OTC (-D), ornithine transcarbamylase
(deficiency); PA, propionic aciduria; RDA, recommended daily allowance;
SAA, single amino acids (L-valine and/or L-isoleucine supplied as a supple-
ment, either independently or in combination); UCD, urea-cycle disorders;
WHO, World Health Organization; Ws, Wilcoxon rank sum test.
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IMD) are provided in the acknowledgment section.
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BCAA ratios, AAMs-UCD seemed to help UCD patients obtain normal BCAA
levels. In patients with OTC-D, CPS1-D, and HHH syndrome, selective L-citrulline
seemed preferable to selective L-arginine supplementation.
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1 | INTRODUCTION
Organic acidurias (OAD) and urea-cycle disorders (UCD)
are rare inherited disorders affecting amino acid and protein
metabolism. Their estimated incidence is 1 in 1 000 000 to
50 000 newborns per individual disease.1,2 OAD (methyl-
malonic aciduria [MMA; mutase deficiency OMIM
#251000, CblA #251100, CblB #251110] and propionic
aciduria [PA; OMIM #606054]) are caused by deficiencies
of the enzymes needed for the breakdown of branched-chain
amino acids (BCAA), L-valine, and L-isoleucine in MMA
and PA. UCD, that is, inherited deficiency of N-
acetylglutamate synthase (OMIM #237310), carbamylpho-
sphate synthetase 1 deficiency (CPS1-D) (EC 6.3.4.16;
OMIM #237300), ornithine transcarbamylase deficiency
(OTC-D) (EC 2.1.3.3; OMIM #311250), argininosuccinate
synthetase deficiency (ASS-D) (EC 6.3.4.5; OMIM
#215700), argininosuccinate lyase deficiency (ASL-D)
(EC 4.3.2.1; OMIM #207900), arginase 1 deficiency
(OMIM #207800), and hyperornithinemia-hyperammone-
mia-homocitrullinuria (HHH) syndrome (OMIM #238970),
are caused by deficiencies of the enzymes and transporter
needed for the urea-cycle. If left untreated, ammonium and
other toxic metabolites accumulate.
In OAD patients, long-term treatment consists of reduc-
ing natural protein intake to prevent intoxication while
allowing normal growth.3 Although, when necessary,
precursor-free amino acid mixtures (AAM) (AAMs-OAD:
amino acid mixtures in OAD) can be supplemented without
inducing intoxication, there has recently been some debate
on their use with respect to the relative high L-leucine con-
tent influencing other plasma BCAA levels.3–6 In some
patients, single amino acids (SAA) can be supplied to fine-
tune dietary treatment, though there is no international con-
sensus on the use of either AAMs-OAD or SAA.7 In UCD
patients, the purpose of dietary treatment is to reduce the
nitrogen load. In the most severe cases, treatment consists of
a protein-restricted diet (either with or without the use of
AAM-UCD [amino acid mixture in UCD]), supplemented
with L-arginine and/or L-citrulline to support the urea-
cycle.8 Most patients also receive nitrogen scavengers. In
patients with mild phenotypes, treatment can be less strict,
ranging from a self-initiated vegetarian diet to a natural pro-
tein restriction without nitrogen scavengers and other sup-
plements. In both OAD and UCD, additional caloric intake
to maintain anabolism is necessary.9
In daily practice, dietary treatment is currently very
diverse.4,10 If long-term outcome in these patients is to be
improved, it is essential that treatment is optimized. The
guideline proposed by Baumgartner et al for the dietary
treatment of patients with MMA and PA11 suggest that “the
FAO/WHO/UNU (2007) safe levels of protein intake are a
useful guide for protein prescription.” The guideline sug-
gests that “synthetic protein should form part of the total
protein intake if natural protein tolerance is below FAO/-
WHO/UNU (2007) safe levels,”11 and the Genetic Metabolic
Dietitian International guideline on PA recommends that
AAMs-OAD (which lack L-isoleucine and L-valine) should
be added to achieve 100% to 120% of recommended daily
allowance (RDA) in those patients who tolerate a natural
protein intake less than 100% RDA (Southeast Regional
Newborn Screening and Genetics Collaborative [SERC]12).
However, there is no guideline available on the amount of
synthetic protein intake as percentage of total protein intake
in those patients requiring supplemental amino acids. The
guideline for UCD proposed by Häberle et al13 likewise sug-
gests that the FAO/WHO/UNU requirements are used for
protein intake. The guideline provides recommendations on
the amount of synthetic protein intake as a percentage of the
total protein intake for patients who require supplemental
amino acids (recommendation: 20%-30%). The same guide-
line also propose recommendations on dosages of L-
citrulline and/or L-arginine treatment (L-arginine dose:
<20 kg body weight: 100-200 mg/kg/d, >20 kg body
weight: 2.5-5 g/m2/d, and L-citrulline dose:
100-200 mg/kg/d). However, these dietary and supplemental
recommendations are based on expert opinion. There are
neither outcome data with respect to recommendations on
appropriate plasma amino acid levels, nor are there clear rec-
ommendations on whether L-citrulline or L-arginine treat-
ment is preferred in any of the following: CPS1-D, OTC-D,
and HHH syndrome.
If optimized treatment is feasible, it is likely to improve
outcome in OAD and UCD patients. To establish whether or
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not treatment is sufficient, it is very important to evaluate
dietary and supplemental treatment in a large cohort of OAD
and UCD patients. We evaluated data from the first visit
recorded in the registry from OAD and UCD patients in the
European registry and network for Intoxication type Meta-
bolic Diseases (E-IMD) (a) to compare their current long-
term dietary and supplemental treatment with the existing
guideline; and (b) to study the plasma amino acids levels in
patients with this prescribed treatment.
2 | METHODS
2.1 | Patient registry and inclusion/exclusion
criteria
The European registry and network for Intoxication type
Metabolic Diseases (E-IMD; URLs: http://www.e-imd.org
[website]; https://www.eimd-registry.org [registry]) is a
European project that was initiated in 2011 and now
includes a web-based patient registry containing comprehen-
sive follow-up data on more than 1200 individuals with
OAD and UCD. A detailed overview of the E-IMD was pub-
lished previously.14 The data in the E-IMD registry were
entered by clinicians and dieticians. The dietary information
in this registry was the diet prescribed, which does not nec-
essarily equal the consumed diet. The study was approved
by the local ethics committee of the coordinating center
(University Hospital Heidelberg) and by all clinical partners.
The current publication project was evaluated by the scien-
tific board and approved by the executive board of the
E-IMD consortium. All the procedures followed were in
accordance with the ethical standards of the committee
responsible for human experimentation (institutional and
national) and with the Helsinki Declaration of 1975 as
revised in 2000. Informed consent with regard to being
included in the study was obtained from all patients or their
legal guardians prior to being included in the study in coun-
tries where this was needed by law.
In this cross-sectional study, we included all data from
the first visits recorded in the registry and all visits included
were during stable metabolic period. We included MMA
(mut-, mut0, cblA, and cblB), PA, OTC-D females and
males, CPS1-D, HHH syndrome, ASS-D, and ASL-D
patients. CblA and CblB patients were included as the
majority of them were symptomatic and they were also trea-
ted with a natural protein restriction. We excluded patients
with other inherited metabolic diseases, those with an uncon-
firmed suspicion of an OAD or UCD, those with MMA
CblC and CblD subtypes and unclassified type, and those
who had received a kidney or liver transplantation or had
other serious unrelated comorbidities, such as Down syn-
drome, kernicterus, or fetal alcohol syndrome. We
furthermore excluded those without information on the pre-
scribed dietary treatment and those without information on
clinical symptoms (symptomatic or not). Clinically symp-
tomatic patients were defined as presenting with a metabolic
crisis or long-term complications.
2.2 | Data analysis
Synthetic protein was defined as a protein-equivalent of spe-
cialized AAM-OAD/UCD and SAA. L-valine and/or L-
isoleucine were supplied independently or in combination as
SAA. Total protein prescription was calculated by adding
natural protein and synthetic protein prescription. Protein
prescription (natural, synthetic, and total) data from the first
visit recorded in the registry was compared with the WHO
RDA15 (Geneva, Switzerland). Synthetic vs total protein
prescription (ratio) was calculated by dividing the amount of
synthetic protein % RDA by total protein % RDA. Informa-
tion on the amino-acid content of AAMs-OAD/UCD was
obtained from the manufacturers. Supplementation with L-
arginine and/or L-citrulline and the provision of sodium phe-
nylbutyrate were both compared with current recommenda-
tions.13 Plasma amino acid levels were compared with the
amino acid reference values provided in Table 2.1.5 of the
“Laboratory Guide to the Methods in Biochemical Genetics”
by Duran.16
On the basis of their common metabolic amino acid dis-
turbances, we combined the following disorders in several
analyses: (a) MMA and PA; (b) inherited deficiency of ASS-
D, ASL-D; (c) OTC-D males, CPS1-D, and HHH syndrome,
and (d) as a separate group OTC-D females.
2.3 | Statistical analysis
SPSS (IBM SPSS Statistics 24.0, IBM Corp., Armonk, NY,
USA) was used for descriptive statistics (percentages, mean,
SD, median, and range). Normality was examined using the
Kolmogorov-Smirnov test and quantile-quantile (Q-Q) plots.
We corrected the P-values per outcome for the subgroup
analyses by using the Holm method. Student's t test was per-
formed to compare means if distribution was Gaussian and
Wilcoxon rank sum test (Ws) if distribution was nonnormal.
If there were dichotomous parameters in a small sample size
Fisher's exact test was performed to determine statistical sig-
nificance between groups and if there were dichotomous
parameters in a large sample size chi-square test was per-
formed. One-way analysis of variance was performed to
compare more than two groups. To compare L-citrulline and
L-arginine prescription against the guideline, body-surface
area was calculated with the Mosteller formula. To identify
variables that had significant associations with plasma amino
acid levels, we used backward stepwise linear regression
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analysis to explain the relationship between five independent
variables on plasma amino acids. As forward methods pro-
duce suppressor effects, we performed backward linear
regression.17 Five independent variables were used in the
multiple regression analysis: protein prescription (natural [%
RDA] and synthetic); use of single BCAAs (yes/no); age at
visit; clinically symptomatic (yes/no); and, in UCD, use of
sodium phenylbutyrate (yes/no). On the basis of the amount
of L-arginine/L-citrulline prescription and of selective L-
citrulline vs L-arginine supplementation, we also used back-
ward stepwise linear regression to identify factors that had
an association with plasma L-arginine levels in OTC-D and
CPS1-D and HHH syndrome.
3 | RESULTS
3.1 | Description of the study population
Two hundred and seventy-one MMA and PA patients and
361 UCD patients had been registered between 1 February
2011 and 20 May 2016 (Supporting Information, Tables S1
and S4). In patients with MMA and PA as well as in patients
with UCD, OTC-D females excluded, 82% was symptom-
atic. A total of 67% of females with OTC-D were symptom-
atic. In total, 73% of patients with OAD and UCD were
diagnosed by selective metabolic testing, 13% by newborn
screening, 13% by high-risk family or population screening,
and 1% by prenatal testing. Most patients were from Europe
(95%), the remainder from Taiwan (2%), the United States
(2%), India (0.8%), and Japan (0.2%). Median age at first
visit recorded in the registry was 9.3 years (5%-95% percen-
tile: 0.4-35.6). The median time from diagnosis until the first
visit recorded in the registry was 6.6 years (5%-95% percen-
tile: 0.2-23.4). Information on participating countries and
disease groups is provided in Table S2.
3.2 | MMA and PA
3.2.1 | MMA, PA, and protein prescription
A total of 92% (250/271) MMA, PA patients received a pro-
tein restricted diet (Figure S1). Natural protein prescription
was according to and above the RDA in 62% (155/250).
Symptomatic MMA, PA patients received a lower natural
and total protein prescription % RDA than asymptomatic
patients (Table S3, Figure 1A). A few patients were pre-
scribed a natural protein intake <50% or >200% RDA
(Figure 1A). Various (29) AAMs-OAD were provided by a
total of six companies and used for a majority of MMA and
PA patients (Figure S1). AAMs-OAD were free of L-valine
and L-isoleucine, while the rest of their content varied
(Table S4). Median protein prescription through AAMs-
OAD was 0.50 g/kg/d (5-95% percentile: 0.18-1.20). SAA
were supplied in only 17% of those with MMA (24/144) and
20% of those with PA (25/127). Ninety percent of those who
received SAA (44/49) were also prescribed AAM-OAD. In
patients who received synthetic protein, natural protein pre-
scription was according to and above the RDA in the major-
ity (58%, 96/166) (Figure 2, Table S3). The mean amounts
of synthetic protein as a percentage of total protein prescrip-
tion was 40% (SD ±15.2). In patients with MMA, those with
the Mut0 subtype were prescribed the lowest natural protein
% RDA. AAMs-OAD were most frequently used in Mut0
and CblB patients (Table S5).
Protein prescription within the different countries varied,
with a median natural protein prescription of 112% RDA, a
total protein prescription of 159% RDA and a synthetic vs
total protein prescription of 40% (Table S2). A high natural
protein prescription was seen in the Austria (n = 12), Tai-
wan (n = 7), and Romania (n = 2) and the highest total pro-
tein prescription in Czech Republic (n = 10), Spain
(n = 20), Romania (n = 2), the United States (n = 10), and
Japan (n = 1). The synthetic vs total protein prescription
was highest in United Kingdom (n = 1), Japan (n = 1),
Denmark (n = 4), Spain (n = 13), and Portugal (n = 2)
(Table S2). Compared to the other countries, AAM-OAD
was not applied in Serbia and Taiwan.
3.2.2 | Impact of dietary management on
plasma amino acids in MMA, PA
Plasma BCAA levels were reported in 66% (180/271) of the
MMA and PA patients (Table S1). In individuals with
MMA and PA plasma, L-valine and L-isoleucine levels both
lay below the lowest reference ranges in 57% and 55% of the
patients, respectively (Figure 3A). Symptomatic MMA and
PA patients who were prescribed AAM-OAD had lower
plasma L-valine and L-isoleucine levels than those without
(Figure 4, Table S3). Linear regression analysis showed that
the plasma L-valine was positively associated with the
amount of natural protein prescription % RDA and nega-
tively associated with the amount of L-leucine prescription
derived from AAM-OAD (Table 3c). Plasma amino acid
levels of L-isoleucine, L-valine, and L-leucine were the low-
est in patients with Mut0 and cblB phenotype (Table S5). In
MMA and PA median plasma, L-isoleucine:L-leucine:L-
valine ratio was 1:2.5:2.9 (reference value: 1:2: 4). Patients
with AAM-OAD had ratio of 1:3.0:3.2, while those without
AAM-OAD had ratio of 1:1.9:3.3. The ratio of L-leucine vs
L-isoleucine plasma levels (Ws = 4088.0, Z = −4.590,
P < 0.001) as well as the ratio of L-leucine vs L-valine
plasma levels (Ws = 3569.5, Z = −6.084, P < 0.001) were
significantly higher in patients who received AAM-OAD
compared to those without.
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3.3 | Urea-cycle disorders
3.3.1 | UCD and protein prescription
A total of 80% (289/361) of the UCD patients received a
protein-restricted diet (Figure 1). Median natural protein pre-
scription in symptomatic and asymptomatic patients was close
to or above the RDA; in the majority of UCD subgroups, total
protein prescription was above the RDA (Figure 1A-D). Several
patients were prescribed a natural protein intake protein <50%
or >200% RDA (Figure 1B-D). For UCD 21 different AAMs-
UCD were provided by a total of five companies. AAMs-UCD
were supplemented with BCAA (L-valine, L-isoleucine, and L-
leucine) (Table S4). AAMs-UCD were used for 32% (114/361)
of the patients (Figure 1) and median protein prescription
through AAM-UCD was 0.28 g/kg/d (range: 0.04-1.17 g/kg/d).
Symptomatic patients who received AAM-UCD had a
lower natural protein % RDA prescribed than those who did
not receive AAM-UCD in the CPS1-D, OTC-D male, and
HHH-syndrome subgroup (Table 3b). In the ASS-D, ASL-D
and CPS1-D, OTC-D male and HHH-syndrome subgroups,
natural protein prescription in symptomatic patients taking
AAM-UCD lay below the RDA (Figure 2). SAA of BCAA
were supplied in only 3% (11/361); 3/11 of those who
received SAA were also prescribed AAM-UCD. The mean
amounts of synthetic protein as a percentage of total protein
prescription were as follows in the following groups: 31% in
the ASS-D and ASL-D subgroup (SD ±18.2), 32% in the
CPS1-D, OTCD-male, and HHH subgroup (SD ±11.7) and
28% (SD ±14.2) in OTC-D females.
Protein prescription within the different countries varied,
there was a high median natural protein prescription in Poland
(n = 9), Denmark (n = 10), and India (n = 4), while a low
median natural protein prescription in Austria (n = 3), Italy
(n = 39), and United Kingdom (n = 8). Austria and the United
Kingdom had a relatively high synthetic vs total protein pre-
scription and thereby a total protein prescription according to
recommendations, while Italy had a low total protein prescrip-
tion. AAMs-UCD were prescribed in the majority of patients in
the Netherlands, Austria and Greece, Czech Republic, while in
the minority in all other countries (Table S2).
3.3.2 | Sodium phenylbutyrate in UCD
Sodium phenylbutyrate was provided in 37% of the UCD patients
(134/361). In the CPS1-D, OTC-D male and HHH-syndrome
subgroup, prescribed natural protein and total protein % RDA
was lower in those prescribed sodium phenylbutyrate treatment
than in those who were not (Table S3B). Sodium phenylbutyrate
was applied in the majority of patients in Germany, the Nether-
lands, Croatia, Czech Republic, and Taiwan (Table S2D).
3.3.3 | Impact of dietary management and
sodium phenylbutyrate on BCAAs in UCD
In 76% of UCD patients (277/361), BCAA levels were reported
(Table S1). In total UCD, plasma L-valine, L-isoleucine, and L-
leucine levels lay below the levels of reference values in 18%,
30%, and 31% of the patients, respectively (Figure 3B-D).
Table S3B shows plasma BCAA levels of the ASS-D, ASL-D
subgroup, OTC-D male, CPS1-D, HHH syndrome subgroup,
and OTC-D female subgroup in symptomatic vs asymptomatic
patients and in those with a natural protein restricted diet vs
those without. In these UCD subgroups, plasma BCAA levels
in patients who received AAM-UCD did not differ from those
who did not receive AAM-UCD (Table S3B). In total UCD
patients, linear regression analysis showed that plasma L-valine,
L-isoleucine, and L-leucine were associated with sodium phe-
nylbutyrate treatment and age at visit (Table S3D). The UCD
patients had a plasma L-isoleucine:L-leucine:L-valine ratio of
1:1.7:3.7 (reference value: 1:2:4). Patients who received AAM-
UCD had a ratio of 1:1.7:3.7 and those who did not receive
AAM-UCD had ratio of 1:1.9:3.7.
3.3.4 | L-arginine and/or L-citrulline
treatment in UCD
L-arginine was provided in most ASS-D and ASL-D
patients, that is, in 95% of the symptomatic patients (90/95)
and 86% of the asymptomatic patients (18/21). In 31% of
ASS-D (18/58) and 31% of the ASL-D patients (14/45), L-
arginine-supplemented doses were above the maximum
recommended guideline (6 g/d13). Individuals who received
L-arginine in the ASS-D and ASL-D subgroup had lower
natural protein % RDA and total protein % RDA prescription
than those who did not receive L-arginine treatment
(Table S3B).
In the CPS1-D, OTC-D male and HHH-syndrome sub-
group, 86% of the symptomatic patients (82/95) and 59%
of the asymptomatic patients (13/22) were prescribed L-
citrulline and/or L-arginine. One or both of these amino
FIGURE 1 Protein prescription in patients with methylmalonic aciduria (MMA) and propionic aciduria (PA) (A); patients with
argininosuccinate synthetase deficiency (ASS-D) or argininosuccinate lyase deficiency (ASL-D) (B); patients with carbamylphosphate synthetase
1 deficiency (CPS1-D), males with ornithine transcarbamylase deficiency (OTC-D) or patients with hyperornithinemia-hyperammonemia-
homocitrullinuria (HHH) syndrome (C); and in females with OTC-D (D). Gray boxes indicate symptomatic patients and black boxes indicate
asymptomatic patients. Synthetic protein indicates the amounts only for patients receiving synthetic protein. Circles: outliers; whiskers: 5 to
95 percentile; horizontal line: median; *P < 0.05
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acids were also prescribed in 79% of the symptomatic
females with OTC-D (68/86) and in 21% of the asymp-
tomatic females (9/42). In those who received L-citrulline
and/or L-arginine, selective supplementation with L-
citrulline was provided in 44% (76/172); a combination of
L-citrulline and L-arginine was provided in 20% (34/172);
and selective L-arginine supplementation was provided in
36% (62/172). Many patients were prescribed L-citrulline
(44% [48/109]) and L-arginine (24% [22/92]) above recom-
mended dose.13
3.3.5 | UCD and levels of plasma L-arginine
and L-citrulline
In the subgroup of patients with CPS1-D, OTC-D [male and
female] and HHH syndrome, patients who were prescribed
selective L-citrulline supplementation had higher plasma L-
arginine levels than those who were prescribed only L-arginine
(Ws = 2745.5, Z = −3.066, P = 0.002) and they had higher
plasma L-arginine levels than those without supplementation
(Ws = 1406.0, Z = −5.109, P < 0.001) (Figure S2). Plasma
L-arginine levels in patients who received L-citrulline only did
not differ from those in patients who received a combination
of L-citrulline and L-arginine (Figure S2). The difference in
plasma L-arginine levels between symptomatic and asymptom-
atic patients can be found in Table S3B. Plasma L-arginine
levels did not differ between OTC-D males and females. The
ratio of OTC-D male vs female did not differ within patients
receiving either L-citrulline or L-arginine or a combination of
these two. Patients (CPS1-D, OTC-D [male and female] and
HHH syndrome) who received either L-citrulline, L-arginine,
or a combination of both did not differ with regard to the age
at visit, prescription of natural protein % RDA, and prescrip-
tion of protein derived from AAM-UCD. However, the mean
L-arginine prescription (mg/kg/d) in patients who received L-
arginine was lower than the mean L-citrulline prescription
(mg/kg/d) in patients who received L-citrulline (Ws = 3397.0,
Z = −2.518, P = 0.012). Regression analysis showed that
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plasma L-arginine levels were associated with selective L-
citrulline therapy vs L-arginine monotherapy (β-coefficient =
0.250, P = 0.007) (R2 = 0.062, R2Adjusted = 0.054), while the
dose of either L-arginine or L-citrulline was not significantly
associated with plasma L-arginine levels in the regression
analysis.
4 | DISCUSSION
The purpose of this cross-sectional study was to evaluate
current prescribed long-term dietary and supplemental treat-
ment in OAD and UCD. We used the E-IMD registry to sur-
vey dietary management approaches of 271 OAD and
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FIGURE 3 Plasma L-valine, L-isoleucine, L-leucine levels in patients with methylmalonic aciduria (MMA) and propionic aciduria (PA) (A);
patients with argininosuccinate synthetase deficiency (ASS-D) or argininosuccinate lyase deficiency (ASL-D) (B); patients with carbamylphosphate
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361 UCD patients to compare their current long-term dietary
and supplemental treatment with the existing guideline; and
to study the plasma amino acids levels in a total of
457 patients with this prescribed treatment. It is essential to
evaluate this treatment, not only because long-term outcome
in OAD and UCD continues to be disappointing, but also
because newborn screening for these diseases is upcoming
in an increasing number of countries.
We have three main findings. First, plasma L-valine and
L-isoleucine levels were very low in most patients with
MMA and PA, mainly in symptomatic patients who received
AAM-OAD (which lack L-valine and L-isoleucine), while
median daily natural protein prescription was consistent with
the current RDA. The high L-leucine content in AAM-OAD
seemed to affect the plasma L-valine levels and lead to
abnormal ratios of plasma L-leucine:L-isoleucine and L-leu-
cine:L-valine.
Second, of patients with UCD plasma BCAA levels lay
below reference ranges in approximately 20% to 30%. While
natural protein prescription lay below the RDA in most
symptomatic patients who received AAM-UCD, plasma L-
valine and L-isoleucine levels and L-isoleucine:L-leucine:L-
valine ratio were similar to those in patients who did not
receive AAM-UCD (which contain essential amino acids).
Sodium phenylbutyrate was correlated with low BCAA
levels as previously reported.18,19 Third, plasma L-arginine
levels were significantly higher in patients with CPS1-D,
OTC-D, and HHH syndrome who were prescribed selective
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FIGURE 4 Plasma L-valine, L-isoleucine, and L-leucine levels in patients with methylmalonic aciduria (MMA) and propionic aciduria (PA).
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L-citrulline supplementation than in patients who were pre-
scribed no supplementation or selective L-arginine
supplementation.
Some limitations of this study and of the registry should
be addressed. First, as no diary-based data was available on
protein intake and there was no data on the patients' adher-
ence to dietary treatment, we were unable to analyze actual
dietary intake and neither total BCAA intake. Furthermore,
quality of protein consumed was not known. In this study,
we assumed that the patients took all the prescribed
amounts. The large number of patients included in this study
can give general information. As a next step actual dietary
intake and intake of BCAAs and its effect should be evalu-
ated. Second, in this study kilocalorie intake was not incor-
porated and should be further studied in upcoming studies.
Third, there was a high variability in the AAMs-OAD/UCD
prescribed and they should be studied in more detail to spe-
cifically determine their effects. Fourth, the quantitative
amino acid analyses were only a single measurement and
not all patients included had BCAA levels measured. Our
cross-sectional approach did not allow easy identification of
predictors of plasma amino acid levels, it is difficult to
assign a cause-effect relationship. Fifth, due to the high
number of participating centers plasma amino acids levels
are determined by various methods and different reference
values are used, which can have impact on the conclusions
drawn. No quality checks were in place to ensure the accu-
racy of data collected at each site. We did not assess the cor-
rectness of measurements and the differences between
contributing laboratories. However, most laboratories partic-
ipate regularly in external quality assessment (ERNDIM).
Furthermore, the registry does not record the interval
between the last intake and sampling of amino-acid plasma
levels. However, as compartmentalization of plasma amino
acids can affect the interpretation of plasma amino acid
levels, samples should be taken accurately between 3.5 and
4 hours after the last meal.20 Last, there can be a bias in the
patients included, since some countries have high numbers
of OAD and UCD, but this is not reflected in the E-IMD reg-
istry. All the limitations specified here require attention in
future studies.
4.1 | MMA, PA: Protein prescription, AAM-
OAD, and plasma amino acid levels
Our results show that while natural protein prescription was
often close to the RDA and total protein prescription was
even above the RDA, with current dietary prescription the
majority of patients had plasma BCAA concentrations below
the reference ranges. The low BCAA levels in MMA and
PA were previously reported by others4,5,21,22 as well as the
observation that daily natural protein prescription was
according to the current RDA in MMA and PA.23,24 Toward
improving patient care, it thus seems necessary to fine-tune
plasma BCAA levels in individual patients. BCAAs are
essential for keeping up anabolism and a decrease in plasma
BCAA concentrations can herald an acute metabolic crisis.18
Furthermore, BCAAs are essential for supporting normal
growth and development.25–27
Since a low natural protein intake can be potentially
harmful, that is, low BCAA levels, one should ensure that
each patient achieves a higher natural protein intake in a
way that does not cause metabolic instability. Protein pre-
scription is currently based on the recommendations pro-
vided by the WHO 200715 (Geneva, Switzerland). While
these recommendations are based on individuals consuming
protein of a high biological value, the proteins commonly
used by OAD patients are not only of low biological value,
but are also poorly digestible.24 Consequently, the WHO
2007 recommendation does not seem applicable to these
patients, an appropriate guideline for their protein prescrip-
tion is necessary. However, due to interpatient variability
this may be hard to achieve.
In OAD, AAM products are free of L-isoleucine, L-
methionine, L-threonine, and L-valine, since these amino
acids are precursors of toxic metabolites. While the guide-
line suggests prescribing AAM-OAD in those patients with
a natural protein prescription below the RDA, we observed
that the majority of those who received AAM-OAD had nat-
ural protein prescription that was according to and above the
RDA. Nevertheless, our results show significantly lower
plasma L-valine and L-isoleucine levels in symptomatic
patients who received AAM-OAD. Those who received
AAM-OAD are; in view of the very low L-valine and L-
isoleucine levels, likely to be at risk of decompensations and
growth retardation, and potentially of long-term complica-
tions. It is noteworthy that, in a small cohort of MMA
patients, a high intake of L-leucine derived from AAM-
OAD was associated with lower L-valine and L-isoleucine
plasma levels.5 This could possibly be explained by means
of the competitive interaction of BCAA on the same recep-
tors (such as the large neutral amino acid transporter,
LAT128). We confirm this inverse relationship between L-
leucine intake derived from AAM-OAD and plasma L-
valine levels in our large patient cohort (of MMA and PA
patients) with correction for covariates such as natural pro-
tein prescription. We furthermore showed that L-leucine:L-
isoleucine as well as L-leucine:L-valine ratios were higher in
those who received AAM-OAD vs those who did not, which
is in line with a study by Myles et al.6 In patients whose nat-
ural protein intake cannot be raised, L-valine and L-
isoleucine plasma levels may be optimized by reducing the
L-leucine content of AAM-OAD. However, as the coeffi-
cients of the negative correlation between L-leucine derived
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from AAM-OAD and plasma L-valine and L-isoleucine
levels were small, it is possible that such a reduction will be
effective only in a small number of patients. It may also be
hazardous: although our data do not confirm this, further
reducing the daily L-leucine intake might lead to even lower
L-leucine plasma levels than found (low plasma L-leucine
levels were previously reported22,23,29), and thereby increase
the risk of catabolism. In conclusion, AAMs-OAD for
MMA and PA patients should be prescribed with care and
with full awareness of their potentially harmful
consequences.6
In MMA and PA patients, supplementation with SAA
can play a role in dietary treatment.7 In the overall group of
MMA, PA patients, the L-isoleucine:L-leucine:L-valine ratio
was 1:2.5:3.0 and in those patients without AAM-OAD ratio
was 1:1.9:3.3, which indicates low L-valine levels (normal
L-isoleucine:L-leucine:L-valine ratio is 1:2:416,28). The dis-
turbed BCAA ratios in patients without AAM-OAD could
be due to the low biological value of protein consumed. In
patients where maximal protein tolerance has been reached,
SAA might be an option. In our opinion, calculating BCAA
ratios can give an indication whether or not to increase natu-
ral protein or to supply SAA.
The first step toward better monitoring of OAD patients
was provided by the guideline that recommend monitoring
quantitative amino acids every 3 to 6 months.11 As it is very
difficult to obtain optimal plasma BCAA levels that stimu-
late growth and development without inducing toxicity, we
suggest that individualized patient care might be optimized
by more frequent monitoring of BCAAs plasma levels.
4.2 | UCD: Protein prescription, AAM-UCD,
and plasma amino acid levels
Natural protein prescription was often close to the RDA and
total protein prescription was even above the RDA in UCD
patients. This could be due to the fact that in this study we
looked into protein prescription, which is not necessarily
equal to the intake. Interestingly, several patients were pre-
scribed high natural protein intake and total protein intake
(>200% RDA), which is highly important to be aware of
since this puts the patients at risk for hyperammonemia and
renal disease. The risk for low plasma BCAA levels is high-
est in those who received sodium phenylbutyrate.18,19,30,31
In UCD patients, AAMs-UCD are supplemented with L-
valine, L-isoleucine, and L-leucine. We found that the natu-
ral protein prescribed in symptomatic UCD patients who
received AAM-UCD was lower than recommended, and sig-
nificantly lower than that in patients without AAM-UCD.
Due to AAM-UCD (median dose 0.28 g/kg/d) total protein
prescription was consistent with recommendations. We
observed that UCD patients who received AAM-UCD—and
thus a lower natural protein prescription—achieved plasma
L-isoleucine and L-valine levels and L-isoleucine:L-leucine:
L-valine ratios similar to patients without AAM-UCD. This
suggests that AAMs-UCD have a beneficial effect in UCD
in stable disease period.
4.3 | UCD: L-arginine and/or L-citrulline
To date there has been no clear-cut evidence that the efficacy
of L-citrulline is greater than that of L-arginine for OTC-D,
CPS1-D, and HHH syndrome.13 Now, for the first time, we
show that patients who received L-citrulline had higher
plasma L-arginine levels than those who received L-arginine
alone. Plasma L-arginine levels depend on the amount of L-
citrulline and/or L-arginine prescription. The bioavailability
of L-citrulline is greater than that of L-arginine,32,33 and sup-
plementation with L-citrulline leads to higher plasma L-
arginine concentrations than supplementation with L-argi-
nine. This supports the notion that it is preferable to use L-
citrulline for patients with CPS1-D, OTC-D, and HHH syn-
drome. Importantly, L-citrulline is more expensive than L-
arginine.13
In this study, we surveyed long-term prescribed dietary
treatment and amino acid supplementation in OAD and
UCD patients in the E-IMD registry, taking the limitations
of this study into consideration, with the aim to improve
treatment. In future studies the possible harmful conse-
quences (ie, the number of decompensations, growth, long-
term complications, and mortality) of the very low plasma
BCAA levels in MMA, PA, and UCD patients must be eval-
uated. Recommendations on adequate plasma levels in OAD
and UCD should be formulated and the efficacy of adjusted
treatment (including AAM and/or SAA), without inducing
toxicity, needs to be followed.
5 | CONCLUSION
Current dietary practice in OAD and UCD patients differ
widely. Natural protein prescription was close to the RDA,
but very low BCAA levels and abnormal BCAA plasma
ratios in patients with MMA and PA who were prescribed
AAMs-OAD were observed. UCD patients with a risk of
low plasma BCAA levels seemed to benefit from BCAA-
supplemented AAMs-UCD. Patients with OTC-D, CPS1-D,
and HHH syndrome who received selective L-citrulline sup-
plementation had significantly higher L-arginine plasma
levels than patients who received no supplementation or
selective L-arginine. These results make it possible to further
improve recent treatment recommendations for OAD
and UCD.
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